FDA pharmacologic class
Kinase inhibitors
73 medicines are in FDA's class of kinase inhibitors (kinase inhibitors): dasatinib (Sprycel), everolimus (Afinitor), imatinib (Gleevec), sirolimus (Fyarro), sunitinib (Sutent), erlotinib, nilotinib (Tasigna), nintedanib (Ofev) and 65 more. 14 of the 73 are listed from generic labelers (FDA NDC Directory, October 8, 2026). The lowest pharmacy cost is imatinib mesylate 100 mg tablet at $0.624 per tablet (NADAC).
Which medicines are kinase inhibitors?
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Dasatinib | Sprycel, Phyrago | 14 labelers | $26.46 per tablet 100 mg tablet | No | No current entry | 0 |
| Everolimus | Afinitor, Zortress, Torpenz | 14 labelers | $26.32 per tablet 10 mg tablet | No | A presentation being discontinued | 5 |
| Imatinib | Gleevec, Imkeldi | 20 labelers | $0.624 per tablet 100 mg tablet | No | No current entry | 4 |
| Sirolimus | Fyarro, Hyftor | 17 labelers | $0.723 per tablet 1 mg tablet | Yes | No current entry | 5 |
| Sunitinib | Sutent | 8 labelers | n/a | Yes | No current entry | 3 |
| Erlotinib | none listed | 10 labelers | n/a | No | No current entry | 0 |
| Nilotinib | Tasigna, Danziten, Cavhanza | 6 labelers | n/a | Yes | No current entry | 2 |
| Nintedanib | Ofev | 11 labelers | $13.46 per capsule 150 mg capsule | No | No current entry | 0 |
| Bosutinib | Bosulif | 3 labelers | n/a | No | No current entry | 0 |
| Ruxolitinib | Jakafi, Opzelura | none listed | $34.01 per gram 1.5% cream | No | No current entry | 0 |
| Pazopanib | Votrient | 8 labelers | n/a | Yes | No current entry | 1 |
| Palbociclib | Ibrance | none listed | n/a | No | A presentation being discontinued | 0 |
| Sorafenib | Nexavar | 7 labelers | n/a | No | No current entry | 0 |
| Lenvatinib | Lenvima | none listed | n/a | No | No current entry | 0 |
| Larotrectinib | Vitrakvi | none listed | n/a | No | No current entry | 1 |
| Afatinib | Gilotrif | 1 labeler | n/a | No | No current entry | 0 |
| Cabozantinib | Cabometyx, Cometriq | none listed | n/a | No | No current entry | 0 |
| Ibrutinib | Imbruvica | none listed | n/a | No | No current entry | 0 |
| Pemigatinib | Pemazyre | none listed | n/a | No | No current entry | 0 |
| Selpercatinib | Retevmo | none listed | n/a | No | No current entry | 0 |
| Avapritinib | Ayvakit | none listed | n/a | No | No current entry | 0 |
| Crizotinib | Xalkori | none listed | n/a | No | No current entry | 0 |
| Gefitinib | Iressa | 4 labelers | n/a | No | No current entry | 0 |
| Trametinib | Mekinist | none listed | n/a | No | No current entry | 0 |
| Abemaciclib | Verzenio | none listed | n/a | No | No current entry | 0 |
| Axitinib | Inlyta | none listed | n/a | No | No current entry | 0 |
| Brigatinib | Alunbrig | none listed | n/a | No | No current entry | 0 |
| Capmatinib | Tabrecta | none listed | n/a | No | No current entry | 0 |
| Dabrafenib | Tafinlar | none listed | n/a | No | No current entry | 0 |
| Lapatinib ditosylate | Tykerb | 3 labelers | n/a | Yes | No current entry | 0 |
| Ponatinib | Iclusig | none listed | n/a | Yes | No current entry | 0 |
| Selumetinib | Koselugo | none listed | n/a | No | No current entry | 0 |
| Acalabrutinib | Calquence | none listed | n/a | No | No current entry | 0 |
| Erdafitinib | Balversa | none listed | n/a | No | No current entry | 0 |
| Leniolisib | Joenja | none listed | n/a | No | No current entry | 0 |
| Lorlatinib | Lorbrena | none listed | n/a | No | A presentation being discontinued | 0 |
| Mirdametinib | Gomekli | none listed | n/a | No | No current entry | 0 |
| Momelotinib | Ojjaara | none listed | n/a | No | No current entry | 0 |
| Ribociclib | Kisqali | none listed | $289.72 per unit 600 mg daily dose | No | No current entry | 0 |
| Vimseltinib | Romvimza | none listed | n/a | No | No current entry | 0 |
| Alectinib | Alecensa | none listed | n/a | No | No current entry | 0 |
| Ceritinib | Zykadia | none listed | n/a | No | No current entry | 0 |
| Futibatinib | Lytgobi | none listed | n/a | No | No current entry | 0 |
| Idelalisib | Zydelig | none listed | n/a | No | A presentation being discontinued | 0 |
| Inavolisib | Itovebi | none listed | n/a | No | No current entry | 0 |
| Lazertinib | Lazcluze | none listed | n/a | No | No current entry | 0 |
| Neratinib | Nerlynx | none listed | n/a | No | No current entry | 0 |
| Pirtobrutinib | Jaypirca | none listed | n/a | No | No current entry | 0 |
| Quizartinib | Vanflyta | none listed | n/a | Yes | No current entry | 0 |
| Repotrectinib | Augtyro | none listed | n/a | No | No current entry | 0 |
| Ritlecitinib | Litfulo | none listed | n/a | Yes | No current entry | 0 |
| Tivozanib | Fotivda | none listed | n/a | No | No current entry | 0 |
| Tovorafenib | Ojemda | none listed | n/a | No | No current entry | 0 |
| Trilaciclib | Cosela | none listed | n/a | No | No current entry | 0 |
| Tucatinib | Tukysa | none listed | n/a | No | No current entry | 0 |
| Vandetanib | Caprelsa | none listed | n/a | Yes | No current entry | 0 |
| Zanubrutinib | Brukinsa | none listed | n/a | No | No current entry | 0 |
| Cobimetinib | Cotellic | none listed | n/a | No | No current entry | 1 |
| Gedatolisib | Revtorpyk | none listed | n/a | No | No current entry | 0 |
| Midostaurin | Rydapt | none listed | n/a | No | No current entry | 0 |
| Pacritinib | Vonjo | none listed | n/a | No | No current entry | 0 |
| Pexidartinib | Turalio | none listed | n/a | Yes | No current entry | 0 |
| Pralsetinib | Gavreto | none listed | n/a | Yes | No current entry | 0 |
| Regorafenib | Stivarga | none listed | n/a | Yes | No current entry | 0 |
| Remibrutinib | Rhapsido | none listed | $72.46 per tablet 25 mg tablet | No | No current entry | 0 |
| Rilzabrutinib | Wayrilz | none listed | n/a | No | No current entry | 0 |
| Ripretinib | Qinlock | none listed | n/a | No | No current entry | 0 |
| Taletrectinib adipate | Ibtrozi | none listed | n/a | No | No current entry | 0 |
| Tepotinib | Tepmetko | none listed | n/a | No | No current entry | 0 |
| Vemurafenib | Zelboraf | none listed | n/a | No | No current entry | 0 |
| Zongertinib | Hernexeos | none listed | n/a | No | No current entry | 0 |
| Osimertinib | Tagrisso | none listed | n/a | No | No current entry | 0 |
| Lytgobi | none listed | none listed | n/a | No | No current entry | 0 |
Source: FDA Established Pharmacologic Class (NDC Directory, openFDA); CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)
What do pharmacies pay?
Each medicine's most widely listed form, per unit, in the NADAC survey: what pharmacies paid, not what a patient pays; strengths differ, so compare like with like.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price